Payment overview · 2025
General Payments
$514.03
26 reported records · 15 companies
Healthcare provider profile · identity verified
Mita Gupta, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HYANNIS, MA · NPI 1750390894
Verified facts
What the public records show
CMS Open Payments records show Mita Gupta, M.D. received $514.03 in general payments during 2025 across 26 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.81 | 12.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.77 | 12.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.16 | 11.5% | 3 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $51.94 | 10.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.10 | 9.4% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $28.56 | 5.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.98 | 5.4% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $26.76 | 5.2% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $26.71 | 5.2% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.78 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.34 | 4.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.80 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.93 | 3.7% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $16.14 | 3.1% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $14.25 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $514.03 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.81 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.77 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.16 | 3 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $51.94 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.10 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.39 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $28.56 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $27.98 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $26.76 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $26.76 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $26.76 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $26.71 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 740 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 657 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 487 | 138 |
| Lisinopril | Lisinopril | 467 | 123 |
| Eliquis | Apixaban | 385 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 347 | 102 |
| Trazodone Hcl | Trazodone Hcl | 342 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 324 | 84 |
| Omeprazole | Omeprazole | 305 | 97 |
| Sertraline Hcl | Sertraline Hcl | 299 | 67 |
| Furosemide | Furosemide | 271 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 256 | 69 |
| Losartan Potassium | Losartan Potassium | 241 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 58 |
| Lorazepam | Lorazepam | 213 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 56 |
| Gabapentin | Gabapentin | 179 | 62 |
| Simvastatin | Simvastatin | 176 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 154 | 43 |
| Famotidine | Famotidine | 153 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 150 | 41 |
| Allopurinol | Allopurinol | 137 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 56 |
| Tramadol Hcl | Tramadol Hcl | 126 | 35 |
| Jardiance | Empagliflozin | 118 | 17 |
| Metformin Hcl | Metformin Hcl | 118 | 37 |
| Oxycodone Hcl | Oxycodone Hcl | 115 | 30 |
| Valsartan | Valsartan | 115 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 59 |
| Potassium Chloride | Potassium Chloride | 108 | 31 |
| Mirtazapine | Mirtazapine | 100 | 32 |
| Atenolol | Atenolol | 94 | 22 |
| Finasteride | Finasteride | 93 | 25 |
| Alendronate Sodium | Alendronate Sodium | 91 | 32 |
| Donepezil Hcl | Donepezil Hcl | 90 | 22 |
| Synthroid | Levothyroxine Sodium | 86 | 26 |
| Spironolactone | Spironolactone | 84 | 24 |
| Metformin Hcl Er | Metformin Hcl | 83 | 20 |
| Gemtesa | Vibegron | 77 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 28 |
| Prednisone | Prednisone | 71 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 15 |
| Alprazolam | Alprazolam | 66 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 20 |
| Risperidone | Risperidone | 62 | suppressed |
| Levetiracetam | Levetiracetam | 61 | suppressed |
| Memantine Hcl | Memantine Hcl | 59 | suppressed |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 16 |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Carvedilol | Carvedilol | 51 | 14 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 46 | 17 |
| Celecoxib | Celecoxib | 46 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 16 |
| Ezetimibe | Ezetimibe | 43 | 18 |
| Ozempic | Semaglutide | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 13 |
| Amoxicillin | Amoxicillin | 41 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 11 |
| Torsemide | Torsemide | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 13 |
| Bupropion Xl | Bupropion Hcl | 39 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 39 | 11 |
| Irbesartan | Irbesartan | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | 13 |
| Diazepam | Diazepam | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 20 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Trospium Chloride | Trospium Chloride | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 12 |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 20 | 14 |
| Estradiol | Estradiol | 20 | 14 |
| Meloxicam | Meloxicam | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Budesonide Ec | Budesonide | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tretinoin | Tretinoin | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Metronidazole | Metronidazole | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $514.03 · 26 records | Bayer Healthcare Pharmaceuticals Inc. | EVENITY, FREESTYLE LIBRE 3, Kerendia, LEQVIO, MOUNJARO, NP Thyroid 60, QULIPTA, RECORLEV, TWIIST, UBRELVY, UNITHROID, VYKAT XR, Wegovy, XYOSTED, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error